CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Oncothyreon Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Oncothyreon Inc.
2601 Fourth Avenue
Suite 500
Phone: (206) 801-2100p:206 801-2100 Seattle, WA  98121  United States Ticker: ONY ONY
This company is no longer actively traded on any major stock exchange.
Business Summary
Oncothyreon Inc. (Oncothyreon) is a clinical-stage biopharmaceutical company. The Company focuses primarily on the development of therapeutic products for the treatment of cancer. The Company’s cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. Oncothyreon’s lead product candidate is Stimuvax, which is a cancer vaccine in Phase III development for non-small cell lung cancer (NSCLC). Oncothyreon has an exclusive, worldwide license to Merck KGaA of Darmstadt, Germany (Merck KGaA), for the development, manufacture and commercialization of Stimuvax. Its pipeline of product candidates is consisted of cancer vaccines and small molecule candidates. The Company’s wholly owned subsidiaries include Oncothyreon Canada Inc., Biomira Management Inc., ProlX Pharmaceuticals Corporation, Biomira International Inc., Biomira BV and Oncothyreon Luxembourg.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/200912/31/2008Yes----

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board Christopher S.Henney 68 9/5/2006 3/8/2005
President, Chief Executive Officer, Director Robert L.Kirkman 60 9/5/2006 9/5/2006
Principal Financial Officer, Principal Accounting Officer ShashiKaran 54 1/1/2009 1/1/2009
7 additional Officers and Directors records available in full report.

Business Names
Business Name
Biomira Inc.
Biomira Inc. (CAN)
Oncothyreon Inc.
ONY
ProlX Pharmaceuticals

General Information
Number of Employees: 18 (As of 12/31/2008)
Outstanding Shares: 25,651,927 (As of 8/12/2009)
Shareholders: 1,372
Stock Exchange: TSE
Fax Number: (206) 801-2101


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023